Outlook Therapeutics, Inc. - 8-K Filing
Outlook Therapeutics set a wholesale acquisition cost of $485 per vial for LYTENAVA™ in the U.S. (Items: 8.01 Other Events)
Tickers: $OTLK
More Regulatory news
- GROOVE BOTANICALS INC. - 10-Q Filing
- Johnson Controls International plc - 10-K Filing
- OLD NATIONAL BANCORP /IN/ - 8-K Filing
- AMTECH SYSTEMS INC - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 8-K Filing
- Bitwise Avalanche ETF - 8-K Filing
- MiNK Therapeutics, Inc. - 10-Q Filing
- Future Vision II Acquisition Corp. - 10-Q Filing
- THUNDER MOUNTAIN GOLD INC - 10-Q Filing
- MiNK Therapeutics, Inc. - 8-K Filing